Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Summit Biolabs
AddedFeb 18, 2024
UpdatedJun 18, 2026
Summit Biolabs

Summit Biolabs

Angel

Summit Biolabs, a Colorado-based molecular diagnostics firm, specializes in detecting head and neck cancer recurrence.

HQ
Aurora, CO, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Summit Biolabs, founded in 2020 and based in Aurora, Colorado, is a molecular diagnostics company specializing in the detection of head and neck cancer recurrence. The company's core mission is to revolutionize molecular testing through pioneering direct-to-PCR technologies, aiming to provide rapid, highly accurate, and robust diagnostic solutions. Summit Biolabs focuses on the healthcare market, particularly in the areas of infectious diseases and oncology, seeking to partner with commercialization entities to deploy their innovative technologies.

Notable figures associated with Summit Biolabs include key researchers and industry experts in molecular diagnostics. The company has gained attention for its transformative approach to molecular testing, leveraging direct-to-PCR techniques that enhance the speed and accuracy of diagnostics. Summit Biolabs' impact is marked by its potential to significantly improve early detection and treatment outcomes for cancer patients, thereby contributing to advancements in personalized medicine and public health.

Summit Biolabs - Quick Facts

When was Summit Biolabs founded?

Summit Biolabs was founded in 2020.

Where is Summit Biolabs' headquarters located?

Summit Biolabs' headquarters is located in Aurora, CO, US.

When was Summit Biolabs' last funding round?

Summit Biolabs' most recent funding round was for $235k (USD) in August 2020.

How much has Summit Biolabs raised to-date?

As of Aug 19, 2020, Summit Biolabs has raised a total of $235k (USD).

How many employees does Summit Biolabs have?

Summit Biolabs has 9 employees as of Feb 5, 2024.

Summit Biolabs - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Molecular Diagnostics
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified